A look on the bright side.
出版信息
Nat Rev Drug Discov. 2005 Feb;4(2):91. doi: 10.1038/nrd1644.
DOI:10.1038/nrd1644
PMID:15756751
Abstract
摘要
相似文献
1
A look on the bright side.
Nat Rev Drug Discov. 2005 Feb;4(2):91. doi: 10.1038/nrd1644.
2
Key factors in the rising cost of new drug discovery and development.新药研发成本上升的关键因素。
Nat Rev Drug Discov. 2004 May;3(5):417-29. doi: 10.1038/nrd1382.
3
Opioid consumption in Italy: industry is not necessarily business--look at the effects.
J Pain Symptom Manage. 2004 May;27(5):391-2. doi: 10.1016/j.jpainsymman.2004.02.009.
4
The special treatment.特殊治疗。
Nat Biotechnol. 2008 May;26(5):487-9. doi: 10.1038/nbt0508-487.
5
A new approach to drug development.一种药物研发的新方法。
N Engl J Med. 2006 Nov 9;355(19):2045; author reply 2046.
6
Avoiding premature licensing.避免过早授权。
Nat Rev Drug Discov. 2006 Dec;5(12):985-6. doi: 10.1038/nrd2203.
7
The pitfalls in the development of biologic therapy.生物疗法开发中的陷阱。
Nat Clin Pract Rheumatol. 2007 Jan;3(1):1. doi: 10.1038/ncprheum0373.
8
A dose of reality for rational therapies.理性疗法的一剂现实良药。
Nat Biotechnol. 2005 Mar;23(3):267. doi: 10.1038/nbt0305-267.
9
The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.在过去十年里，新药批准数量的减少一直是一个备受争议的话题。前言。
Adv Pharmacol. 2009;57:xi-ii. doi: 10.1016/S1054-3589(08)57015-3.
10
Pipeline problems are increasing the urge to merge.管道问题正加剧合并的紧迫性。
Nat Rev Drug Discov. 2006 Dec;5(12):977-9. doi: 10.1038/nrd2206.
Zotero 插件